Literature DB >> 22287661

Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples.

Oemer-Necmi Goek1, Anna Köttgen, Ron C Hoogeveen, Christie M Ballantyne, Josef Coresh, Brad C Astor.   

Abstract

BACKGROUND: Circulating lipoproteins and their protein constituents, apolipoproteins, are risk factors for chronic kidney disease (CKD). The associations between apolipoprotein A1, apolipoprotein B and their ratio with glomerular filtration rate estimated from the new CKD Epidemiology Collaboration (CKD-EPI) equation (eGFR) are not well studied in the general population.
METHODS: Associations between apolipoprotein A1, B and their ratio with the outcomes of eGFR, CKD (eGFR<60 mL/min/1.73 m2) and albuminuria were examined in the Atherosclerosis Risk in Communities study (ARIC, n=10,292, 1996-98) and the Third National Health and Nutrition Examination Survey (NHANES III, n=7023, 1988-91). Cross-sectional multivariable-adjusted analyses were performed using linear and logistic regression. Prospective analyses related baseline apolipoprotein levels to subsequent CKD incidence over 10 years using the ARIC Carotid MRI follow-up cohort (n=1659).
RESULTS: Higher apolipoprotein A1 quartiles were associated with a lower prevalence of CKD [Q4 versus Q1: odds ratio (OR) 0.73, P-trend=0.02 in ARIC; Q4 versus Q1: OR 0.53, P-trend<0.01 in NHANES III] as well as with higher eGFR (P-trend<0.01 in ARIC and NHANES III). No consistent significant associations were found for apolipoprotein B in either study. The apolipoprotein B/A1 ratio was significantly associated with eGFR across quartiles in both studies (P-trend<0.01) and with CKD in ARIC (Q4 versus Q1: OR 1.23, P-trend=0.01). Prospectively, there were trends for the association of apolipoproteins with incident CKD [Q4 versus Q1: incidence rate ratio (IRR)=0.68 for apolipoprotein A1, P-trend=0.1; Q4 versus Q1: IRR=1.35 for apolipoprotein B, P-trend=0.2]. Associations were not systematically stronger when comparing traditional lipids (total cholesterol, low-density lipoprotein or high-density lipoprotein) to apolipoproteins.
CONCLUSIONS: Higher serum apolipoprotein A1 was associated with lower prevalence of CKD and higher eGFR estimated by the CKD-EPI equation in two large multiethnic population-based samples. While apolipoprotein B showed no consistent associations, a higher apolipoprotein B/A1 ratio was significantly associated with lower eGFR in both studies. The direction and magnitude of the longitudinal associations between apolipoproteins and CKD incidence were overall similar to those observed cross-sectionally. No consistent differences became apparent between traditional lipids and apolipoproteins.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22287661      PMCID: PMC3471548          DOI: 10.1093/ndt/gfr795

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  53 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.

Authors:  G Walldius; I Jungner; I Holme; A H Aastveit; W Kolar; E Steiner
Journal:  Lancet       Date:  2001-12-15       Impact factor: 79.321

3.  Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men.

Authors:  Philippa J Talmud; Emma Hawe; George J Miller; Steve E Humphries
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-11-01       Impact factor: 8.311

4.  Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).

Authors:  A M Gotto; E Whitney; E A Stein; D R Shapiro; M Clearfield; S Weis; J Y Jou; A Langendörfer; P A Beere; D J Watson; J R Downs; J S de Cani
Journal:  Circulation       Date:  2000-02-08       Impact factor: 29.690

5.  Associations of HDL, HDL(2), and HDL(3) cholesterol and apolipoproteins A-I and B with lifestyle factors in healthy women and men: the Stanford Five City Project.

Authors:  C D Gardner; D L Tribble; D R Young; D Ahn; S P Fortmann
Journal:  Prev Med       Date:  2000-10       Impact factor: 4.018

6.  Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  A R Sharrett; C M Ballantyne; S A Coady; G Heiss; P D Sorlie; D Catellier; W Patsch
Journal:  Circulation       Date:  2001-09-04       Impact factor: 29.690

7.  Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats.

Authors:  Jaap A Joles; Uta Kunter; Ulf Janssen; Wilhelm Kriz; Ton J Rabelink; Hein A Koomans; Jürgen Floege
Journal:  J Am Soc Nephrol       Date:  2000-04       Impact factor: 10.121

8.  Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate.

Authors:  Josef Coresh; Brad C Astor; Geraldine McQuillan; John Kusek; Tom Greene; Frederick Van Lente; Andrew S Levey
Journal:  Am J Kidney Dis       Date:  2002-05       Impact factor: 8.860

9.  Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy.

Authors:  Alicia J Jenkins; Timothy J Lyons; Deyi Zheng; James D Otvos; Daniel T Lackland; Daniel McGee; W Timothy Garvey; Richard L Klein
Journal:  Kidney Int       Date:  2003-09       Impact factor: 10.612

10.  Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: comparison with apoprotein CIII.

Authors:  Tsutomu Hirano; Taro Sakaue; Asako Misaki; Satoru Murayama; Toshihiro Takahashi; Kenta Okada; Hiroko Takeuchi; Gen Yoshino; Mitsuru Adachi
Journal:  Kidney Int       Date:  2003-06       Impact factor: 10.612

View more
  20 in total

Review 1.  The effect of chronic kidney disease on lipid metabolism.

Authors:  Neris Dincer; Tuncay Dagel; Baris Afsar; Adrian Covic; Alberto Ortiz; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2018-12-05       Impact factor: 2.370

Review 2.  Morbidity and mortality associated with obesity.

Authors:  Mahmoud Abdelaal; Carel W le Roux; Neil G Docherty
Journal:  Ann Transl Med       Date:  2017-04

3.  Changes in serum inflammatory markers are associated with changes in apolipoprotein A1 but not B after the initiation of dialysis.

Authors:  George A Kaysen; Lorien S Dalrymple; Barbara Grimes; Glenn M Chertow; John Kornak; Kirsten L Johansen
Journal:  Nephrol Dial Transplant       Date:  2013-09-05       Impact factor: 5.992

Review 4.  Apolipoprotein-AI and AIBP synergetic anti-inflammation as vascular diseases therapy: the new perspective.

Authors:  Ampadu O Jackson; Ganiyu A Rahman; Shiyin Long
Journal:  Mol Cell Biochem       Date:  2021-04-03       Impact factor: 3.396

Review 5.  The Roles of Fatty Acids and Apolipoproteins in the Kidneys.

Authors:  Xiaoyue Pan
Journal:  Metabolites       Date:  2022-05-20

6.  Effects of dietary macronutrients on serum urate: results from the OmniHeart trial.

Authors:  Matthew J Belanger; Christina C Wee; Kenneth J Mukamal; Edgar R Miller; Frank M Sacks; Lawrence J Appel; Robert H Shmerling; Hyon K Choi; Stephen P Juraschek
Journal:  Am J Clin Nutr       Date:  2021-06-01       Impact factor: 7.045

7.  Relationship between hyperuricemia and lipid profiles in US adults.

Authors:  Tao-Chun Peng; Chung-Ching Wang; Tung-Wei Kao; James Yi-Hsin Chan; Ya-Hui Yang; Yaw-Wen Chang; Wei-Liang Chen
Journal:  Biomed Res Int       Date:  2015-01-05       Impact factor: 3.411

8.  Engulfment and cell motility 1 (ELMO1) and apolipoprotein A1 (APOA1) as candidate genes for sickle cell nephropathy.

Authors:  Santosh L Saraf; Xu Zhang; Binal N Shah; Rasha Raslan; Bamidele O Tayo; James P Lash; Nora Franceschini; Victor R Gordeuk
Journal:  Br J Haematol       Date:  2020-11-20       Impact factor: 6.998

9.  Association of Early Renal Dysfunction with Lipid Profile Parameters among Hypertensives in Kazakhstan.

Authors:  Alma Nurtazina; Dana Kozhakhmetova; Daulet Dautov; Nurzhanat Khaidarova; Vijay Kumar Chattu
Journal:  Diagnostics (Basel)       Date:  2021-05-12

10.  Causal Associations of Urate With Cardiovascular Risk Factors: Two-Sample Mendelian Randomization.

Authors:  Thitiya Lukkunaprasit; Sasivimol Rattanasiri; Boonsong Ongphiphadhanakul; Gareth J McKay; John Attia; Ammarin Thakkinstian
Journal:  Front Genet       Date:  2021-07-08       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.